Cargando…
Management of osteoporosis in the aging male: Focus on zoledronic acid
Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fract...
Autores principales: | Piper, Paul K, Gruntmanis, Ugis |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739630/ https://www.ncbi.nlm.nih.gov/pubmed/19750231 |
Ejemplares similares
-
Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
por: Carmona, Raj, et al.
Publicado: (2009) -
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
por: Dalle Carbonare, Luca, et al.
Publicado: (2010) -
Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel, Agnès, et al.
Publicado: (2011) -
Zoledronic acid infusion for prevention and treatment of osteoporosis
por: Sunyecz, John A
Publicado: (2010) -
Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis
por: Lu, Yanhui, et al.
Publicado: (2013)